To quantify the incremental treatment burden of adverse events (AEs) among patients with Lennox-Gastaut syndrome (LGS) receiving antiseizure medication (ASM).
No takes yet. Share an insight, caveat, or question.
Shah et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: